Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Optimal dose regimen of epcoritamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma - analyses of pharmacokinetics and exposure-response relationships of epcore FL-1 Phase 3 study

View Full Paper
Ask AI
Bookmark
Share

Authors

BNBehnam Noorani

Discussion

Loading...

Member takes

Overview

Phase 3 trial demonstrates that 48 mg of epcoritamab improves progression-free survival in relapsed follicular lymphoma, suggesting a superior safety profile.

Key Points

  • Assess the optimal dosing regimen of epcoritamab in combination with lenalidomide and rituximab for patients with relapsed or refractory follicular lymphoma.
  • Open-label, randomized Phase 3 trial (EPCORE FL-1)
  • Investigated two dosing arms: 48 mg and 24 mg epcoritamab with R2
  • Analyzed pharmacokinetics (PK) and exposure-response (E-R) relationships
  • Higher exposure of 48 mg resulted in improved progression-free survival compared to 24 mg
  • 3-step up dosing regimen reduced the incidence of cytokine release syndrome compared to 2-step regimen
  • No increase in Grade ≥3 adverse events associated with higher epcoritamab exposure

Cite This Study

Behnam Noorani (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d451https://doi.org/10.1182/blood-2025-1820
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Exposure–Response Analyses to Inform the Optimal Epcoritamab Monotherapy Dosing Regimen in Relapsed or Refractory Follicular Lymphoma2026
  2. 2primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma2025 · 2 citations
  3. 3Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma2025 · 14 citations
  4. 4Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial2025
  5. 5Abstract 3732: Peripheral pharmacodynamic activity of epcoritamab as monotherapy and in combination with rituximab + lenalidomide in patients with follicular lymphoma2024